Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) CEO Simon Morriss is back with Proactive’s Elisha Newell to outline the company’s latest endeavours in the predictive genetics space. Lauded as a pioneer in clinical genetics tech, GTG is working on early-stage tools that help clinicians and patients proactively manage their health. Morriss says the company’s product suite is geared towards personalised, non-invasive testing and risk assessments, all designed to accelerate a global transition to genomic-integrated healthcare.
Genetic Technologies embraces global vision for genomic-integrated healthcare
